Go Pro

Braveheart Bio (BRVE) Stock Forecast & Price Target

Braveheart Bio logo
$25.50 -1.94 (-7.07%)
As of 08/31/2026 04:00 PM Eastern

Braveheart Bio - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
0
Buy
5

Based on 5 Wall Street analysts who have issued ratings for Braveheart Bio in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 5 have given a buy rating for BRVE.

Consensus Price Target

$45.25
77.45% Upside
According to the 5 analysts' twelve-month price targets for Braveheart Bio, the average price target is $45.25. The highest price target for BRVE is $48.00, while the lowest price target for BRVE is $40.00. The average price target represents a forecasted upside of 77.45% from the current price of $25.50.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BRVE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Braveheart Bio and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BRVE Analyst Ratings Over Time

TypeCurrent Forecast
9/1/25 to 9/1/26
1 Month Ago
8/2/25 to 8/2/26
3 Months Ago
6/3/25 to 6/3/26
1 Year Ago
9/1/24 to 9/1/25
Strong Buy
0 Strong Buy rating(s)
N/A N/A N/A
Buy
5 Buy rating(s)
N/A N/A N/A
Hold
0 Hold rating(s)
N/A N/A N/A
Sell
0 Sell rating(s)
N/A N/A N/A
Consensus Price Target$45.25N/AN/AN/A
Forecasted Upside77.45% UpsideN/AN/AN/A
Consensus RatingBuyN/AN/AN/A

BRVE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BRVE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Braveheart Bio Stock vs. The Competition

TypeBraveheart Bio CompaniesBroader Market
Consensus Rating Score
3.00
1.64
2.53
Consensus RatingBuyReduceModerate Buy
Predicted Upside77.45% Upside156.47% Upside13.78% Upside
News Sentiment Rating
Neutral News

See Recent BRVE News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/31/2026
TD Cowen logo
TD Cowen
3 of 5 stars
Initiated CoverageBuy
8/31/2026 Initiated CoverageBuy$48.00+74.93%
8/31/2026
Salveen Richter
Salveen Richter
5 of 5 stars
Initiated CoverageBuy$48.00+74.93%
8/31/2026Initiated CoverageBuy$45.00+63.99%
8/31/2026Initiated CoverageOverweight$40.00+45.77%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:04 AM ET.


BRVE Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Braveheart Bio is $45.25, with a high forecast of $48.00 and a low forecast of $40.00.

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Braveheart Bio in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BRVE shares.

According to analysts, Braveheart Bio's stock has a predicted upside of 77.45% based on their 12-month stock forecasts.

Braveheart Bio has been rated by research analysts at Cantor Fitzgerald, Jefferies Financial Group, Stifel Nicolaus, TD Cowen, and The Goldman Sachs Group in the past 90 days.

Analysts like Braveheart Bio more than other "" companies. The consensus rating for Braveheart Bio is Buy while the average consensus rating for "" companies is Reduce. Learn more on how BRVE compares to other companies.


MarketBeat monitors more than a dozen sources for Braveheart Bio analyst ratings, with the most recent rating issued on 8/31/2026.
From Our Partners